Letters Archives – Page 9 of 10 – Treatment Action Group

Marketing and Use of QuantiFERON-TB Gold

May 16, 2013
Chad Cipiti

14 May 2013 Peer M. Schatz Chief Executive Officer and Managing Director QIAGEN Benelux B.V. Spoorstraat 50 5911 KJ Venlo The Netherlands Email: peer.schatz@qiagen.com RE: Marketing and Use of QuantiFERON-TB Gold for active TB in India and high TB burden…

Micardis Sign-on Letter to Boehringer Ingelheim

November 8, 2012
Chad Cipiti

Letter urging the company to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317.

Washington Call for Access to HCV Diagnostics, Treatment and Care for All!

July 27, 2012
Chad Cipiti

Letter from TAG and civil society organizations undersigned grassroots civil society groups and non-governmental organizations asking for universal access to HCV voluntary testing and treatment.

TAG and the TB CAB Send Open Letter to Otsuka

May 31, 2012
Chad Cipiti

TAG and the TB CAB send open letter to Otsuka to expedite plans to develop a pre-approval access program for delamanid for patients in urgent need, determine if delamanid is safe to use with bedaquiline, and develop the drug for pediatric use as rapidly and safely as possible.

TAG and TB CAB Issue Open Letter to Janssen

May 31, 2012
Chad Cipiti

TAG and TB CAB issue an open letter to Janssen, bedaquiline’s sponsor, about the need to accelerate pediatric research, to determine the safety of using bedaquiline and delamanid together, and to support Janssen’s compassionate use program to provide access to bedaquiline for people in urgent need in places where the drug has not yet been approved.

TAG and TB CAB Letter On Drug-Drug Interaction in TB Drug Development

May 31, 2012
Chad Cipiti

TAG and TB CAB send letter to FDA and to the EMA to encourage crucial regulatory harmonization on endpoints for tuberculosis drug development, and to encourage Otsuka and Janssen to conduct necessary drug-drug interaction studies on bedaquiline and delamanid.

Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)

May 24, 2012
Chad Cipiti

May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…

Letter to NIAID Director Anthony Fauci Opposing the HVTN 505 Vaccine Trial

May 11, 2012
Chad Cipiti

TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.

TAG and TB CAB Letter Asking for Price Reduction for GeneXpert Machines

April 16, 2012
Chad Cipiti

TAG and the TB CAB send open letter to Cepheid calling for price reduction for the GeneXpert machines and the Xpert MTB/RIF cartridges.

TAG and TB Cab Open Letter RE: Early Access to Bedaquiline

April 11, 2012
Chad Cipiti

TAG and the TB CAB support South African advocates, doctors, and organizations in their call for early access to bedaquiline by sending an open letter to the South African Medicines Control Council (MCC).